ClinicalTrials.gg
CompletedNCT03315338Updated May 24, 2019

First-in-human Study in Healthy Subjects

A Phase 1 interventional study of CORT118335, 25 mg and Prednisone Oral Tablet in Healthy, sponsored by Corcept Therapeutics. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-05-24.

Sponsored by Corcept Therapeutics · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
143
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This initial Phase I study will evaluate the safety, tolerability, and pharmacokinetics (PK) of single and multiple ascending doses of CORT118335, the effect of concomitant administration with food on exposure to CORT118335, and its pharmacological effect in healthy subjects.

Read the detailed description

This is a 5-part, single-center study of single and multiple ascending doses of CORT118335 in healthy subjects.

Parts I and 4 of the study are double-blind, randomized, placebo-controlled assessments of single-ascending doses (SAD) of CORT118335. Subjects will be enrolled sequentially into 1 of up 8 cohorts (Part 1, Cohorts A to D [Cohorts E to G have been cancelled]; Part 4, Cohorts A to D), each containing 8 subjects. Within each cohort, 6 subjects will be randomly assigned to receive a single dose of CORT118335 and 2 subjects will be randomly assigned to receive a single dose of matching placebo.

Part 2 Cohort A, food-effect, will be an open-label 2-way crossover study in one cohort of 12 subjects, randomized in a 1:1 ratio to receive a single dose of CORT118335 once after an overnight fast and once after a high-fat breakfast or the alternate sequence, over 2 study periods separated by a washout of at least 7 days/5 half-lives.

Part 2 Cohort B, PD cohort, will be a double-blind, randomized, placebo-controlled, 3-way cross-over study and will serve as proof of pharmacological effect (GR modulation) for CORT118335. Subjects will be randomized in a 1:1:1 ratio to receive placebo, and two dose levels of CORT118335 in one of three treatment sequences across 3 study periods separated by washouts of at least 7 days/5 half-lives. On each occasion, the ability of CORT118335 to ameliorate the pharmacological effects of a single dose of prednisone will be measured.

Parts 3 and 5 are double-blind, randomized, placebo-controlled assessments of multiple oral ascending doses of CORT118335. Subjects will be enrolled sequentially into 1 of up to 4 cohorts (Part 1 Cohort A [Cohorts B to D have been cancelled; Part 5 Cohorts A to C), each containing 12 subjects. Within each cohort, 9 subjects will be randomly assigned to receive CORT118335 and 3 subjects to receive matching placebo daily for 14 days.

Different formulations of CORT118335 will be used in Parts 1, 2 and 3, and in Parts 4 and 5.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Corcept Therapeutics is the lead sponsor of 73 studies on the registry; 3 are open to participants now.

Of its 32 completed or terminated interventional studies of FDA-regulated products, 9 (28%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male subjects or non-pregnant, non-lactating healthy female subjects of non-
  • Age 18 to 60 years
  • (BMI) of 18.0 to 30.0 kg/m2
  • Weight of ≤102 kg
  • Must be willing and able to communicate and participate in the whole study
  • Morning serum cortisol of 5 μg/dL to 23 μg/dL (138 nmol/L to 635 nmol/L) at screening and/or Day -1 for multiple dose cohorts
  • Must provide written
  • Must agree to use an adequate method of
  • Must agree to adhere to study restrictions

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received any IMP in a clinical research study within the 3 months before the first dose in this study
  • Subjects who are study site or Sponsor employees, or immediate family members of a study site or Sponsor employee
  • Subjects who have previously been enrolled in this study
  • Males who have a pregnant partner
  • History of any drug or alcohol abuse in the year before the first dose in this study
  • Regular alcohol consumption in male subjects >21 units per week and female subjects >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Current smokers and those who have smoked within the 6 months before the first dose in this study. A breath carbon monoxide reading of greater than 10 ppm at screening or on admission
  • Current users of e-cigarettes and nicotine replacement products and those who have used these products within the 6 months before the first dose in this study
  • Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the Investigator at screening
  • abnormal biochemistry, hematology or urinalysis as judged by the Investigator
  • Positive drugs of abuse test result at screening or on admission (amphetamines, barbiturates, benzodiazepines, cocaine, marijuana/cannabis, methadone, methamphetamine/ecstasy, morphine/opiates, phencyclidine, tricyclic antidepressants)
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
  • Subject has active renal and/or hepatic disease, as evidenced by:

    • an estimated (eGFR) of \<60 mL/min/1.73m2 using Modification of Diet in Renal Disease (MDRD) equation at screening
    • and/or AST >1.5 times the at screening or on admission
    • subjects with borderline results can have these tests repeated once.
  • History of clinically significant cardiovascular, renal, hepatic, endocrine, metabolic, respiratory, gastrointestinal or neurological disease as judged by the Investigator
  • Subject had any form of cancer within the 2 years before first dose in this study*, with the exception of basal cell and/or squamous cell cancer of the skin that has been treated completely and is without evidence of local recurrence or
  • Subject has a history and/or symptoms of adrenal insufficiency
  • Subject has consumed liquorice or other glycyrrhetic acid derivatives regularly, in the judgement of the Investigator, in the 6 months before the first dose of study medication
  • Subject has a history of jaundice and/or subject has had a cholecystectomy
  • Subject has a history of clinically significant gastrointestinal disease including gastroesophageal reflux disease, malabsorption syndrome, colon cancer, chronic colitis, Crohn's disease, inflammatory bowel disease, gastroparesis, constipation, chronic diarrhoea, obstruction, gastrointestinal bleeding, and/or peptic ulcers
  • Subject has a condition that could be aggravated by and/or mineralocorticoid blockade (e.g., asthma, any chronic inflammatory condition) or activation (e.g., immunodeficiency, active infection)
  • Subjects with inactive seasonal hay fever may be included. Subjects with childhood (aged less than 18 years) asthma may be included provided they have had no symptoms and required no treatment for at least 5 years
  • Subjects with a interval of >450 msec at screening or pre-dose, based on the mean of three ECGs
  • History of additional risk factors for torsades de pointes (e.g., heart failure, hypokalaemia, family history of long QT syndrome)
  • Supine heart rate at rest of \<40 bpm or >100 bpm. BP out with the following ranges: diastolic BP 40-90; systolic BP 90-140 (subjects aged 18-45 year) and 90-160 (subjects aged >45 year). Heart rate and blood pressure can be retested twice in the supine position at intervals of 5 min on a given day at screening and admission.
  • Serious adverse reaction or serious to any drug or the formulation including glucose/fructose intolerance for the standard oral glucose tolerance test (OGTT)
  • Presence or history of clinically significant allergy requiring treatment, as judged by the Investigator.
  • Donation or loss of greater than 400 mL of blood within the 3 months before first study dose
  • Subjects who are taking, or have taken, any prescribed, over-the-counter drug (other than 4 g per day paracetamol) or herbal remedies within 14 days, or for which 5 times the medication's elimination half-life will not be completed if longer, before the first dose of study medication. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the Investigator and Sponsor's medical monitor. Standard dose multivitamins are permitted throughout the study period
  • Subjects who are currently using glucocorticoids or have a history of systemic glucocorticoid use at any dose within the last 12 months or 3 months for inhaled products
  • Subjects who are taking, or have taken enzyme inducers within 30 days before the first dose of study medication
  • Subject is expected to require use of any medication (with the exception of standard dose multivitamins) during the study period
  • Subject has a history or presence of any medical condition or disease which, in the opinion of the Investigator, could interfere with the conduct of the study or could put the subject at unacceptable risk. This specifically includes any subject with flu or flu-like symptoms
  • Failure to satisfy the Investigator of fitness to participate for any other reason
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
143 participants (actual)

Study arms

  • Experimental
    SAD Part 1 Active Cohort A

    CORT118335, 25 mg

    Drug: CORT118335, 25 mg

  • Placebo comparator
    SAD Part 1 Placebo oral capsule Cohort A

    Drug: Placebo oral capsule

  • Experimental
    SAD Part 1 Active Cohort B

    CORT118335, 75mg

    Drug: CORT118335, 75mg

  • Placebo comparator
    SAD Part 1 Placebo Cohort B

    Drug: Placebo oral capsule

  • Experimental
    SAD Part 1 Active Cohort C

    CORT118335, 225mg

    Drug: CORT118335, 225mg

  • Placebo comparator
    SAD Part 1 Placebo Cohort C

    Drug: Placebo oral capsule

  • Experimental
    SAD Part 1 Active Cohort D

    CORT118335, 675mg

    Drug: CORT118335, 675mg

  • Placebo comparator
    SAD Part 1 Placebo Cohort D

    Drug: Placebo oral capsule

  • Experimental
    SAD Part 2 Active Cohort A, Fasting

    CORT118335, 600mg, is supplied as capsules for oral dosing given after an overnight fast

    Drug: CORT118335, 600mg

  • Experimental
    SAD Part 2 Active Cohort A, Fed

    CORT118335, 600mg, is supplied as capsules for oral dosing given after a high-fat breakfast

    Drug: CORT118335, 600mg

  • Placebo comparator
    SAD Part 2 Placebo PD Effect Cohort B

    Drug: Prednisone Oral Tablet · Drug: Glucose · Drug: Placebo oral capsule

  • Experimental
    SAD Part 2 Active PD Effect Cohort B: 630mg of CORT118335

    Drug: Prednisone Oral Tablet · Drug: Glucose · Drug: CORT118335, 630mg

  • Experimental
    SAD Part 2 Active PD Effect Cohort B: 675mg of CORT118335

    Drug: Prednisone Oral Tablet · Drug: Glucose · Drug: CORT118335, 675mg

  • Experimental
    MAD Part 3 Active Cohort A

    CORT118335, 375mg qd for 14 days

    Drug: CORT118335, 375mg

  • Placebo comparator
    MAD Part 3 Placebo Cohort A

    Placebo qd for 14 days

    Drug: Placebo oral capsule

  • Experimental
    SAD Part 4 Active Cohort A

    CORT118335, 100mg

    Drug: CORT118335, 100mg

  • Placebo comparator
    SAD Part 4 Placebo Cohort A

    Drug: Placebo oral suspension

  • Experimental
    SAD Part 4 Active Cohort B

    CORT118335, 300mg

    Drug: CORT118335, 300mg

  • Placebo comparator
    SAD Part 4 Placebo Cohort B

    Drug: Placebo oral suspension

  • Experimental
    SAD Part 4 Active Cohort C, Fasting

    CORT118335, 900mg is supplied as suspension for oral dosing given after an overnight fast

    Drug: CORT118335, 900mg

  • Experimental
    SAD Part 4 Active Cohort C, Fed

    CORT118335, 900mg is supplied as suspension for oral dosing given after a high-fat breakfast

    Drug: CORT118335, 900mg

  • Placebo comparator
    SAD Part 4 Placebo Cohort C, Fasting

    Supplied as suspension for oral dosing given after an overnight fast

    Drug: Placebo oral suspension

  • Placebo comparator
    SAD Part 4 Placebo Cohort C, Fed

    Supplied as suspension for oral dosing given after a high-fat breakfast

    Drug: Placebo oral suspension

  • Experimental
    SAD Part 4 Active Cohort Part D

    CORT118335, 1500mg

    Drug: CORT118335, 1500mg

  • Placebo comparator
    SAD Part 4 Placebo Cohort D

    Drug: Placebo oral suspension

  • Experimental
    MAD Part 5 Active Cohort A

    CORT118335, 150mg

    Drug: CORT118335, 150mg

  • Placebo comparator
    MAD Part 5 Placebo Cohort A

    Drug: Placebo oral suspension

  • Experimental
    MAD Part 5 Active Cohort B

    CORT118335, dose to be determined

    Drug: CORT118335, dose to be determined

  • Placebo comparator
    MAD Part 5 Placebo Cohort B

    Drug: Placebo oral suspension

  • Experimental
    MAD Part 5 Active Cohort C

    CORT118335, dose to be determined

    Drug: CORT118335, dose to be determined

  • Placebo comparator
    MAD Part 5 Placebo Cohort C

    Drug: Placebo oral suspension

Interventions

  • CORT118335 is supplied as capsules for oral dosing

  • Challenge Agent, Dose and Route of Administration: Standard release 1x20mg and 1x5mg (25mg total) dose, orally administered.

  • 75 g in 300 mL solution, orally administered

  • DrugPlacebo oral suspension

    Reference Therapy, Dose and Route of Administration: Placebo suspension, orally administered.

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as capsules for oral dosing

  • CORT118335 is supplied as a suspension for oral dosing

  • CORT118335 is supplied as a suspension for oral dosing

  • CORT118335 is supplied as a suspension for oral dosing

  • CORT118335 is supplied as a suspension for oral dosing

  • CORT118335 is supplied as a suspension for oral dosing

  • DrugPlacebo oral capsule

    Placebo capsules, orally administered

  • CORT118335 is supplied as suspension for oral dosing

06

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    Time frame: SAD Cohorts: Day -28 to Day 7; Part 2A Cohorts: Day -28 to Day 14; Part 2B Cohorts: Day -28 to Day 21; MAD Cohorts: Day -28 to Day 21

Secondary outcomes

  1. QT interval corrected for heart rate using Fridericia's formula (QTcF) exposure-response analysis

    Time frame: SAD parts: Pre dose through 24 hours post dose. MAD parts: Pre first dose through 24 hours post final dose of Investigational Medicinal Product (IMP

  2. tlag Pharmacokinetic (PK) parameter

    The elapsed time from dosing at which analyte was first quantifiable in a concentration vs time profile (tlag)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  3. tmax PK parameter

    The time from dosing at which Cmax was apparent (tmax)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  4. Cmax PK parameter

    Maximum observed concentration (Cmax)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  5. tmin (MAD only) PK parameter

    Time from dosing of the minimum plasma drug concentration (tmin)

    Time frame: MAD parts: Pre first dose through 96 hours post final dose of IMP

  6. Cmin (MAD only) PK parameter

    Minimum plasma drug concentration (Cmin)

    Time frame: MAD parts: Pre first dose through 96 hours post final dose of IMP

  7. Clast PK parameter

    Last measurable concentration (Clast)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  8. tlast PK parameter

    Time from dosing of the last measurable concentration (tlast)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  9. t1/2 PK parameter

    The apparent elimination half-life (t1/2)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  10. lambda-z PK parameter

    The slope of the apparent elimination phase (lambda-z)

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  11. AUCinf PK parameter

    Area under the plasma concentration-time curve from time zero to infinity (AUCinf)

    Time frame: SAD parts: Pre dose through 96h post dose; MAD parts: Pre first dose through 96h post final dose of IMP

  12. AUC(0-last) PK parameter

    Area under the curve from 0 time to last measurable concentration \[AUC(0-last)\]

    Time frame: SAD parts: Pre dose through 96 hours post dose; MAD parts: Pre first dose through 96 hours post final dose of IMP

  13. AUC(0-24) PK parameter

    Area under the curve from 0 time to 24 h post dose \[AUC(0-24)\]

    Time frame: SAD parts: Pre dose through 24 hours post dose; MAD parts: Pre first dose through 24 hours post final dose of IMP

  14. Food effect: AUC(0-last) PK parameter

    Time frame: Pre first dose through 96 hours post final dose

  15. Food effect: AUC(0-inf) PK parameter

    Area under the curve from 0 time extrapolated to infinity \[AUC(0-inf)\]

    Time frame: Pre first dose through 96 hours post final dose

  16. Food effect: Cmax PK parameter

    Time frame: Pre first dose through 96 hours post final dose

  17. Pharmacodynamics (PD): peripheral differential white blood cell count

    Time frame: Pre first dose through 24 hours post final dose

  18. PD: serum osteocalcin and adiponectin concentrations

    Time frame: Pre first dose through 24 hours post final dose

  19. PD: messenger ribonucleic acid (mRNA) expression for selected genes in whole blood

    Time frame: Pre first dose through 24 hours post final dose

  20. PD: glucose tolerance

    Time frame: Pre first dose through 24 hours post final dose

  21. Homeostatic model assessment of insulin-resistance (HOMA-IR)

    Time frame: Pre-dose through Day 14

07

Study locations

1 site
  • Quotient Clinical
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Feb 2019, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2017
First posted
Oct 20, 2017
StartActual
Sep 15, 2017
Primary completionActual
Feb 22, 2019
CompletionActual
Feb 22, 2019
Last update
May 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03315338
Responsible party
Sponsor
First posted
Oct 20, 2017
Start date
Sep 15, 2017
Primary completion
Feb 22, 2019
Completion
Feb 22, 2019
Last update
May 24, 2019

Study contacts

Stuart Mair, MBChB, MFPM
principal investigator · Quotient Clinical

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CORT118335 · Prednisone · Glucose

Start the discussion